666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
| Autor: | Blagden, S., Elshani, M., Symeonides, S.N., Skolariki, A., Haris, N.R., Boh, Z.Y., Dickson, A., Um, I.H., Zhang, Y., McKissock, F.G., Oelmann, E., Bloss, J., Cook, N., Evans, T.R.J., Plummer, R., Harrison, D.J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S523-S524 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|